I am pleased to share that Massachusetts General Hospital recently hosted the inaugural Richard Slayman Clinical Xenotransplantation Workshop, co-directed by Dr. Leonardo Riella and Dr. Tatsuo Kawai. This landmark event brought together more than 140 participants from across North America, Europe, and Asia, representing leading voices in surgery, transplantation, immunology, infectious diseases, regulatory science, and biotechnology in xenotransplantation.
Named in honor of Richard Slayman—the first kidney xenotransplant recipient in the world, this workshop marked a pivotal moment in the advancement of clinical xenotransplantation. Over two days, we explored the latest scientific and clinical developments in kidney, heart, and liver xenotransplantation, while also addressing the immunological, physiological, and ethical challenges that lie ahead.
Among the most meaningful moments was the participation of Timothy Andrews, the longest-living recipient of a genetically modified pig kidney, who joined the workshop alongside his wife Karen. More than four months post-transplant, Mr. Andrews continues to thrive with excellent kidney function and will be honored next week by throwing the ceremonial first pitch at a Boston Red Sox game—a powerful symbol of resilience, innovation, and hope.
The workshop also featured a profoundly moving panel on Patients and Family Perspectives, with remarks from Faren Woolery, the partner of Richard Slayman. She offered the following reflection, which encapsulates the spirit of the event:
“Earlier we talked about defining success in xenotransplantation. Although Rick is not here with us, if we think about why he chose to do this—it was to provide hope for those suffering with kidney failure. This workshop represents the hope he envisioned. When we talk about success in environments like this—where we are learning, where we have individuals like Tim who are willing to step up—this is success. Of course, we all wish Rick were here. But continuing the legacy he lived is how we now define success.”
This event reflects MGH’s unwavering commitment to pioneering clinical innovation, compassionate patient care, and collaborative progress. I congratulate Drs. Kawai and Riella, as well as our transplant leadership—Dr. Madsen, Dr. Pierson, and Dr. Shah—for their vision and dedication. I look forward to the continued impact of this groundbreaking work on the future of transplantation.
Richard Slayman Clinical Xenotransplantation Workshop_Riella PDF of Program